CureVac Investors Face Pivotal Week as BioNTech Takeover Hangs in the Balance

Shareholders of the Tübingen-based biotech firm CureVac are approaching a decisive moment. An extraordinary general meeting scheduled for Tuesday, November 25th, will determine the company’s future integration into the vaccine giant BioNTech. However, the proposed acquisition faces significant obstacles, with market skepticism raising questions about whether the deal could collapse at the final hurdle.

The primary challenge lies in the exceptionally high acceptance rate required for the transaction to proceed. A minimum of 80% of CureVac shares must be tendered for the deal to advance, a threshold that substantially exceeds typical market standards for such acquisitions and introduces considerable execution risk. While provisions exist for BioNTech to potentially lower this requirement Read more...